| Cash Flow | 2026-06-30 |
|---|---|
| Net cash used in operating activities from discontinued operations | 0 |
| Net cash used in investing activities from discontinued operations | 0 |
| Net cash provided by financing activities from discontinued operations | 0 |
| Net cash used in discontinued operations | 0 |
| Share-based compensation | 0 |
| Interest income | 0 |
| Amortization of loan discounts | 0 |
| Change in the fair value of financial assets at fair value through profit or loss (see note 8) | 0 |
| Less net loss from discontinued operations | 0 |
| Net income (loss) from continuing operations | 1,812 |
| Net income (loss) | 1,812 |
| Net income (loss) from continuing operations | 1,812 |
| Depreciation and amortization | 452 |
| Deferred taxes | -55 |
| Accrued interest, net | -41 |
| Amortization of deferred debt issuance costs (see notes 7.d. 7.e, 7.f) | 6 |
| Decrease in accounts receivable | -34 |
| Increase in other current assets | 60 |
| Increase in related parties | -89 |
| Increase (decrease) in accounts payable | -133 |
| Decrease (increase) in other payables | -21 |
| Gain arising from deconsolidation of a subsidiary upon loss of control (see note 6.d) | 3,831 |
| Net cash used in operating activities from continuing operations | -1,666 |
| Purchase of property and equipment | 186 |
| Deconsolidation of a subsidiary upon loss of control (see appendix b and note 6.d) | 120 |
| Net cash from acquisition of subsidiaries (see appendix a and notes 6.b, 6.c) | 193 |
| Net cash provided by (used in) investing activities from continuing operations | -113 |
| Receipt of short-term convertible loans | 0 |
| Repayment of short-term bank loans | 0 |
| Change in loan to former parent company | 0 |
| Repayment of short-term convertible loans | 200 |
| Receipt of short-term bank loans | 2 |
| Repayment of long-term bank loans | 391 |
| Proceeds from issuance of shares and warrants in connection with the 2026 private placement (see note 10.d) | 1,400 |
| Proceeds from exercise of warrants | 2,413 |
| Net cash provided by financing activities from continuing operations | 3,224 |
| Increase in cash and cash equivalents and restricted cash | 1,445 |
| Cash and cash equivalents and restricted cash at beginning of period | 1,038 |
| Cash and cash equivalents and restricted cash at end of period | 2,483 |
QUANTUM X LABS INC. (QXL)
QUANTUM X LABS INC. (QXL)